Evidence map›Paper›PMID 33758496›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2021

Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia.

Tyler A Berger, Matthew W Manry, Lucas B Lindsell, James M Osher, Daniel M Miller, Robert E Foster, Christopher D Riemann, Michael R Petersen, Robert A Sisk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tyler A BergerDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Matthew W ManryDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Lucas B LindsellDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
James M OsherDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Daniel M MillerDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Robert E FosterDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Christopher D RiemannDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Michael R PetersenDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
Robert A SiskDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA.
University of Cincinnati · USCincinnati Eye Institute · USCincinnati Children's Hospital Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate if off-label Age-Related Eye Disease Study 2 (AREDS2) supplementation prevents visual and anatomical deterioration in non-proliferative Idiopathic Macular Telangiectasia Type 2 (IMT2). PATIENTS AND

methodsThis is a single-center retrospective, comparative study of 82 IMT2 eyes treated with AREDS2 from January 1st, 2013 to January 1st, 2018. The study analysis consisted of a non-comparative arm, which included all AREDS2 eyes, and a comparative arm (27 AREDS2 and 42 untreated eyes) that only included eyes with complete follow-up data. Eyes were evaluated at baseline, 12 and 24 months. Better/worse eye sub-analysis was performed in the comparative study arm. Primary outcomes were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) anatomical characteristics including largest cavitation diameter, central macular thickness (CMT), and length of ellipsoid zone (EZ) loss at 24 months.

resultsIn the non-comparative arm, AREDS2 eyes showed stable BCVA (0.28 ± 0.18 logMAR at baseline vs 0.26 ± 0.19 logMAR at 24 months; p = 0.35) and OCT anatomical features after 24 months of supplementation. In the comparative arm, BCVA mean difference was greater for untreated eyes at 24 months (-0.09 ± 0.15 vs 0.03 ± 0.11 logMAR; p = <0.001). AREDS2 eyes had decreased cavitary diameter and EZ loss compared to untreated eyes at the study endpoint (p = 0.01 and p = 0.02, respectively). CMT remained stable for both cohorts throughout the study. For better/worse eye analysis, untreated eyes had worse BCVA at 24 months in both better and worse eyes (both p = 0.01). For anatomical outcomes, increases in both EZ loss (p = 0.04) and cavitary diameter (p = 0.001) among untreated eyes were only significant for eyes with worse baseline BCVA.

conclusionOur results suggest that off-label AREDS2 supplementation in non-proliferative IMT2 may prevent anatomical and visual deterioration in a subset of eyes.

Indexed as

antioxidantAREDS2carotenoid supplementationellipsoid zone lossidiopathic macular telangiectasiajuxtafoveal macular telangiectasialuteinmacular telangiectasiaparafoveal telangiectasiaretinal vascular disease

Identifiers

PMID33758496
PMCPMC7979356
OpenAlexW3138604132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.